Research Update

ReNeuron Group plc
16 February 2006

  ReNeuron announces initial pre-clinical data with its ReN004 human stem cell
                         lines for Parkinson's disease

Guildford, UK, 16 February 2006: ReNeuron Group plc (LSE: RENE) today announces
that initial in vivo testing of its ReN004 candidate stem cell lines shows them
to have attributes that may favour the reversal of the neurological deficits
seen in Parkinson's disease.

The human cell lines were generated using ReNeuron's patented c-mycERTAM stem
cell expansion technology, and were pre-screened for both genetic stability and
their ability to differentiate into tyrosine hydroxylase (TH)-expressing
neurons.  TH is a marker for a dopaminergic stem cell phenotype, this cell type
being deficient in patients suffering from Parkinson's disease.

All of the cell lines showed good survival four weeks post-implantation into the
appropriate regions of the rodent brain.  One of the cell lines showed
up-regulation of TH-expressing neurons in the graft area, indicating the
potential for functional efficacy in a pre-clinical model.

These results will be presented at the Keystone Stem Cells (G4) meeting in
Whistler, Canada on 27 March to I April 2006.  The Company is undertaking
further studies with its ReN004 stem cell lines to assess their potential in
pre-clinical models of Parkinson's disease, and hopes to report the results of
these studies later this year.

Commenting on the announcement, Dr John Sinden, Chief Scientific Officer of
ReNeuron, said:

'We are greatly encouraged by these early results with our ReN004 programme for
Parkinson's disease. They again demonstrate the ability of ReNeuron's platform
c-mycERTAM technology to generate stable stem cell lines of relevant types with
potential to treat a variety of disorders both within and outside the central
nervous system.'


Enquiries:

ReNeuron
Michael Hunt, CEO                                       Tel: [phone]
John Sinden, CSO

Financial Dynamics
David Yates                                             Tel: [phone]
Sarah Macleod


Notes to Editors

About Parkinson's disease

Parkinson's disease is a progressive neurodegenerative disease of the basal
ganglia region of the brain, with tremor, rigidity and difficulty initiating
movement being the most common symptoms.  The condition is associated with a
deficiency of the chemical dopamine in the brain.  It is estimated that four
million people worldwide have Parkinson's1 and there is currently no effective
cure for the disease.

1. UK Parkinson's Disease Society

About ReNeuron Group plc

ReNeuron is a leading, UK-based adult stem cell therapy business. The Company is
applying its novel stem cell platform technologies in the development of
ground-breaking stem cell therapies to serve significant and unmet or poorly-met
clinical needs.

ReNeuron has used its c-mycERTAM technology to generate genetically stable
neural stem cell lines. This technology platform has multi-national patent
protection and is fully regulated by means of a chemically-induced safety
switch. Cell growth can therefore be completely arrested prior to in vivo
implantation.

The Company's lead stem cell therapy, ReN001 for chronic stroke disability, is
in late pre-clinical development.  The Company plans to file for approval to
commence initial clinical trials in stroke later this year, with trials
commencing as soon as possible thereafter.

The Company has also generated pre-clinical efficacy data with its ReN005 stem
cell therapy for Huntington's disease, a rare, genetic and fatal
neurodegenerative disorder which affects around 1 in 100,000 people.  This
programme is in pre-clinical development.

In addition to its stroke and Huntington's disease programmes, ReNeuron is
developing stem cell therapies for Parkinson's disease, Type 1 diabetes and
diseases of the retina.

ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell range of cell lines for use in drug discovery applications
in the pharmaceutical industry.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L,
and its warrants are traded under the symbol RENW.L.

Further information on ReNeuron and its products can be found at
www.reneuron.com.

This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.

The terms 'ReNeuron' or 'the Company' refer to ReNeuron Group plc and its
subsidiary undertakings.


                      This information is provided by RNS
            The company news service from the London Stock Exchange